The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Announces Rs. 317 crore investment in new recycling plant
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Modernization and supply chain diversity drive new growth
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
